| Similar Articles |
|---|
 |
BusinessWeek
June 25, 2007
Gene G. Marcial |
Good Results At Bio-Reference Labs Specialty testing is delivering solid earnings for Bio-Reference Laboratories, the third-largest U.S. clinical test outfit.   |
The Motley Fool
June 7, 2007
Ryan Fuhrmann |
Big Gains for a Little Lab-Tester While bigger competitors stumble over each other, Bio-Reference keeps growing. This company may just be a welcome investment alternative as its two larger peers keep getting in each other's way. |
The Motley Fool
June 6, 2007
Ryan Fuhrmann |
Foolish Forecast: Bio-Reference Labs Nudges Competitors The clinical laboratory testing company is set to release it second-quarter earnings report. Investors, here is what you can expect to see. |
The Motley Fool
March 12, 2007
Ryan Fuhrmann |
Esoteric Results at Bio-Reference Labs Bio-Reference Labs is a small firm in the lab-testing field, but worth a look from investors. |
The Motley Fool
September 7, 2005
Stephen D. Simpson |
The Little Lab That Could Bio-Reference is a small business with big potential. The company has an appealing cancer and genomics business (GenPath). For investors seeking successful yet unknown companies, this one is worth watching. |
Chemistry World
May 29, 2014 |
Safety first? Just how safe is working in a laboratory? As Jon Evans discovers, it depends on where you are and who you ask |
The Motley Fool
September 6, 2007
Ryan Fuhrmann |
Bio-Reference Labs Passes the Test Small-cap lab-testing firm Bio-Reference Labs third-quarter results beat analysts projections by a decent margin, again proving it can compete with the big boys in the highly competitive New York metro area. |
Pharmaceutical Executive
March 1, 2013
Keeling & Paz |
Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics. |
The Motley Fool
February 4, 2011
Brian Orelli |
Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you? |
